Amido heteroaromatic compounds

A compound of Formula (I);

• wherein,
• A is selected from
• each RA is independently selected from H, halo, RX, —ORx, and —CN, wherein each RX is independently C1-3 alkyl optionally substituted with one to three F;
• RB is halo, —CHF2, —CF3, —OCHF2 or —OCF3;
• one of X1, X2 and X3 is selected from NH, O and S and the other two of X1, X2 and X3 are independently selected from N and CRY, wherein each RY is independently H, —CN, —C(═O)N(R7)2 or RXA, wherein RXA is independently C1-3 alkyl optionally substituted with one to three F;
• R1 and R2 are such that;
• (i) R1 and R2, taken together with the N atom to which they are attached, form a ring system, wherein the ring system is optionally substituted with one or more RC, wherein each RC is independently selected from F, R3, R4, —O(R4), —O(R5), R5, R6, —OH, —CN, oxo and —C(═O)N(R7A)2;
• (ii) R1 is selected from R8 and R4A, and R2 is selected from R8A and H;
• or
• (iii) R1 is RSA and R2 is R8B;
• each R3 is independently C1-4 alkyl or C3-6 cycloalkyl, each of which are optionally substituted with one or more groups independently selected from R4X, R5X, —O(R4X), —O(R5X) and F;
• each R3X is independently C1-4 alkyl or C3-6 cycloalkyl, each of which are optionally substituted with one or more F;
• each R4 and R4B are independently monocyclic or bicyclic 5 to 9 membered heteroaryl, each of which are optionally substituted with one or more groups independently selected from R4X, —O(R4×), R5X, —O(R5X), —OH, —CN, C1-4 alkoxy, —C(═O)OH, —C(═O)O(C1-4 alkyl), —C(═O)N(R7B)2, R3 and halo;
• R4A is a 5 membered monocyclic heteroaryl, optionally substituted with one or more groups independently selected from R4X, —O(R4X), R5X, —O(R5X), —OH, —CN, C1-4 alkoxy, —C(═O)OH, —C(═O)O(C1-4 alkyl), —C(═O)N(R7B)2, R3 and halo;
• each R5, R5A and R5B are independently phenyl, each of which are optionally substituted with one or more groups independently selected from R4X, —O(R4X), R5X, —O(R5X), —OH, —CN, C1-4 alkoxy, —C(═O)OH, —C(═O)O(C1-4 alkyl), —C(═O)N(R7B)2, R3 and halo;
• each R4X is independently monocyclic or bicyclic 5 to 9 membered heteroaryl, each of which are optionally substituted with one or more groups independently selected from —OH, —CN, C1-4 alkoxy, —C(═O)OH, —C(═O)N(R7B)2, R3X and halo;
• each R5X is independently phenyl, each of which are optionally substituted with one or more groups independently selected from —OH, —CN, C1-4 alkoxy, —C(═O)OH, —C(═O)N(R7B)2, R3X and halo;
• R6 is C1-4 alkoxy optionally substituted with one or more groups independently selected from R4X, R5X and F;
• each R7, R7A, R7B and R7c are independently H, C1-4 alkyl or C3-6 cycloalkyl;
• R8, RBA, R8B are independently C1-4 alkyl or C3-6 cycloalkyl, each of which are optionally substituted with one or more groups independently selected from R4B, R5B, F, —OH, —CN, C1-4 alkoxy, —C(═O)O(C1-4 alkyl) and —C(═O)N(R7X)2 wherein the ring system is a saturated or partly saturated, monocyclic, bicyclic or tricyclic, 4-13 membered ring comprising one N atom, and optionally one or two further heteroatoms independently selected from N, O and S;
• and
• wherein each heteroaryl is independently an aromatic ring containing one or more heteroatoms independently selected from N, O and S,
• or a pharmaceutically acceptable salt thereof.